Creative Biolabs has announced an upgrade to its AI-driven functional protein solutions, designed to accelerate the discovery of multi-receptor agonists for metabolic diseases such as obesity and type 2 diabetes. The platform leverages deep learning to overcome computational challenges in optimizing multi-target affinity and metabolic stability, reducing typical research cycles from years to 2–14 weeks.
The pharmaceutical industry has increasingly focused on dual and triple-receptor agonists—such as GLP-1/GIP/GCGR combinations—following the clinical success of GLP-1 therapies. However, traditional iterative optimization of polypharmacological peptides is labor-intensive, often requiring years of trial and error to balance activation ratios of multiple receptors. Creative Biolabs' proprietary deep learning algorithms simulate receptor-ligand interactions in a high-throughput virtual environment, identifying molecules capable of simultaneously activating multiple biological pathways with precision.
A key technical challenge addressed by the platform is the rapid enzymatic degradation of peptide drugs in vivo. Creative Biolabs' AI calculates and systematically eliminates vulnerable sequence sites, engineering ultra-long-acting profiles that reduce patient dosing frequency. Additionally, the platform relies on high-fidelity pharmacological dataset training to avoid the "garbage in, garbage out" dilemma common in machine learning models. By using carefully curated, function-first data, it accurately predicts ADMET properties early in the pipeline, ensuring generated sequences are potent and free from severe off-target toxicity or unwanted immunogenicity.
The platform also expands chemical space through precision modulation, integrating molecular dynamics simulations to enable rational design of ligands targeting hidden binding pockets. This structural biology approach allows fine-tuning of receptor activity via allosteric modulation, avoiding overstimulation of highly homologous protein families and bypassing resistance mechanisms. "Industrial clients require more than just theoretical binding affinity; they demand manufacturable, highly stable molecules with guaranteed functional activity in biological assays," stated the director of computational biology at Creative Biolabs. "Our deep learning pipelines transition multi-receptor sequence design from a process of serendipity to a highly predictable, automated workflow."
Pharmaceutical partners using the AI pipelines have reported significant reductions in design-test-learn cycles, with early adopters highlighting high predictive accuracy and comprehensive deliverables that bridge in silico predictions and in vitro success. Biotechnology firms and pharmaceutical companies developing pipeline assets for complex metabolic disorders are encouraged to implement these advanced computational workflows. For technical specifications or project consultations, visit Creative Biolabs' official platform.
